
  
    
      
        Background_NNP
        Carbenoxolone_NNP ,_, the_DT succinyl_NN ester_NN of_IN glycyrrhetinic_JJ acid_NN
        [_NN 1_CD ]_NN ,_, is_VBZ now_RB used_VBN in_IN clinical_JJ treatment_NN of_IN ulcer_NN diseases_NNS
        [_NN 2_CD ]_NN ._. It_PRP has_VBZ some_DT pharmacological_JJ properties_NNS such_JJ as_IN :_: the_DT
        inhibition_NN of_IN 11_CD β-hydroxy_JJ steroid_NN dehydrogenase_NN (_( 11_CD β-_NN HSD_NNP )_) [_NN
        1_CD ]_NN ,_, and_CC inhibition_NN of_IN gap_NN junctional_NN intercellular_NN
        communication_NN [_NN 3_CD ]_NN ._. Electrotonic_NNP synaptic_JJ communication_NN
        between_IN neurons_NNS via_IN gap_NN junctions_NNS (_( GJs_NNP )_) is_VBZ increasingly_RB
        recognized_VBN as_IN an_DT important_JJ synchronizing_VBG mechanism_NN in_IN the_DT
        brain_NN ._. The_DT pathogenesis_NNS of_IN abnormal_JJ neuronal_NN synchrony_NN
        underlying_VBG seizures_NNS ,_, formerly_RB thought_VBD to_TO be_VB based_VBN mainly_RB on_IN
        the_DT chemical_NN synaptic_JJ transmission_NN ,_, now_RB includes_VBZ a_DT role_NN of_IN
        gap_NN junctional_NN communication_NN ._. This_DT concept_NN has_VBZ been_VBN
        strengthened_VBN by_IN evidence_NN from_IN several_JJ in_IN vitro_NN models_NNS ,_, in_IN
        which_WDT pharmacological_JJ manipulations_NNS of_IN gap_NN junctional_NN
        communication_NN predictably_RB affect_VB the_DT generation_NN of_IN
        seizures_NNS :_: blockers_NNS diminishing_VBG seizure_NN ,_, and_CC enhancers_NNS
        increasing_VBG the_DT seizures_NNS [_NN 4_CD ]_NN ._. GJ_NNP channels_NNS can_MD contribute_VB
        to_TO the_DT prolongation_NN of_IN epileptiform_NN discharges_NNS [_NN 5_CD ]_NN ._.
        In_IN in_IN vitro_NN studies_NNS ,_, carbenoxolone_NN abolished_VBD the_DT
        generation_NN of_IN full_JJ or_CC partial_JJ ectopic_JJ spike_NN generation_NN ,_, by_IN
        4_CD -_: AP_NNP ,_, in_IN the_DT CA_NNP 
        3_CD region_NN of_IN rat_NN hippocampal_NN slices_NNS [_NN 6_CD ]_NN
        ._. Also_RB carbenoxolone_NN depresses_VBZ spontaneous_JJ epileptiform_NN
        activity_NN in_IN the_DT CA_NNP 
        1_CD region_NN of_IN rat_NN hippocampal_NN slices_NNS [_NN 7_CD ]_NN
        ._. Carbenoxolone_NNP appears_VBZ to_TO cross_VB the_DT blood_NN brain_NN barrier_NN
        about_IN one_CD hour_NN after_IN an_DT intraperitoneal_NN injection_NN in_IN rats_NNS
        as_IN there_EX was_VBD the_DT inhibition_NN of_IN 11_CD -_: β-hydroxysteroid_JJ
        dehydrogenase_NN in_IN multiple_JJ brain_NN regions_NNS [_NN 1_CD ]_NN ._. It_PRP and_CC /_NN or_CC
        its_PRP$ congener_NN glycyrrehetinic_JJ acid_NN may_MD also_RB enter_VB the_DT eyes_NNS
        of_IN humans_NNS ._. Ingestion_NNP of_IN licorice_NN has_VBZ been_VBN reported_VBN to_TO cause_VB
        transient_JJ visual_JJ loss_NN [_NN 8_CD ]_NN ,_, a_DT possible_JJ consequence_NN of_IN
        retinal_JJ gap_NN junction_NN blockade_NN ._.
        Thus_RB ,_, we_PRP considered_VBD the_DT possible_JJ anticonvulsant_NN effect_NN
        of_IN carbenoxolone_NN in_IN animal_NN seizure_NN models_NNS ._.
      
      
        Results_NNS
        In_IN pentylenetetrazole_NN (_( PTZ_NNP )_) model_NN ,_, ED_NNP 50_CD values_NNS of_IN
        diazepam_NN and_CC carbenoxolone_NN were_VBD 1_CD ._. 13_CD mg_NN /_NN kg_NN (_( %_NN 95_CD CL_NNP :_: 0_CD ._. 89_CD ,_,
        1_CD ._. 44_CD )_) and_CC 283_CD ._. 3_LS mg_NN /_NN kg_NN (_( %_NN 95_CD CL_NNP :_: 144_CD ._. 27_CD ,_, 556_CD ._. 29_CD )_) ,_,
        respectively_RB ._.
        In_IN PTZ_NNP model_NN ,_, carbenoxolone_NN increased_VBD the_DT latency_NN of_IN
        seizures_NNS and_CC decreased_VBD the_DT duration_NN of_IN seizures_NNS ,_, dose_NN
        dependently_RB (_( Table_NNP 1_LS )_) ._.
        In_IN maximal_NN electroshock_NN (_( MES_NNP )_) model_NN ,_, carbenoxolone_NN (_( 400_CD
        mg_NN /_NN kg_NN )_) decreased_VBD the_DT duration_NN of_IN tonic_NN seizures_NNS ._. This_DT
        effect_NN was_VBD not_RB statistically_RB significant_JJ in_IN the_DT lower_JJR doses_NNS
        of_IN carbenoxolone_NN ._. This_DT agent_NN could_MD not_RB completely_RB protect_VB
        the_DT mice_NNS against_IN mortality_NN in_IN a_DT dose_NN of_IN 400_CD mg_NN /_NN kg_NN (_( Table_NNP
        2_LS )_) ._.
        In_IN the_DT potentiation_NN of_IN pentobarbitone_NN sleep_NN test_NN ,_,
        carbenoxolone_NN significantly_RB increased_VBD the_DT sleeping_VBG time_NN in_IN
        mice_NNS at_IN doses_NNS of_IN 100_CD ,_, 200_CD and_CC 300_CD mg_NN /_NN kg_NN compared_VBN to_TO
        controls_NNS dose_NN dependently_RB (_( Table_NNP 3_LS )_) ._. Also_RB ,_, carbenoxolone_NN in_IN
        doses_NNS of_IN 100_CD ,_, 200_CD and_CC 300_CD mg_NN /_NN kg_NN decreased_VBD the_DT latency_NN
        compared_VBN to_TO controls_NNS dose_NN dependently_RB and_CC this_DT effect_NN was_VBD
        statistically_RB significant_JJ (_( Table_NNP 3_LS )_) ._.
        In_IN the_DT traction_NN test_NN ,_, carbenoxolone_NN did_VBD not_RB induce_VB a_DT
        muscle_NN relaxant_NN activity_NN significantly_RB up_IN to_TO a_DT dose_NN of_IN 400_CD
        mg_NN /_NN kg_NN ._. Carbenoxolone_NNP (_( 400_CD mg_NN /_NN kg_NN )_) showed_VBD muscle_NN relaxant_NN
        activity_NN compared_VBN to_TO normal_JJ saline_NN ,_, and_CC this_DT effect_NN was_VBD
        more_JJR than_IN diazepam_NN in_IN a_DT dose_NN of_IN 0_CD ._. 25_CD mg_NN /_NN kg_NN (_( Table_NNP 4_LS )_) ._.
        In_IN accelerod_NN performances_NNS ,_, carbenoxolone_NN in_IN the_DT first_JJ
        trial_NN in_IN doses_NNS of_IN 100_CD ,_, 200_CD and_CC 300_CD mg_NN /_NN kg_NN ,_, showed_VBD a_DT decline_NN
        in_IN motor_NN function_NN relative_JJ to_TO normal_JJ saline_NN (_( 10_CD ml_NN /_NN kg_NN )_)
        (_( Table_NNP 5_LS )_) ._. The_DT second_JJ trial_NN ,_, carbenoxolone_NN in_IN doses_NNS of_IN 200_CD
        and_CC 300_CD mg_NN /_NN kg_NN decreased_VBD the_DT riding_VBG time_NN on_IN rotarod_NN compare_VB
        to_TO normal_JJ saline_NN (_( Table_NNP 5_LS )_) ._.
      
      
        Discussion_NNP
        Present_VB results_NNS indicate_VBP that_DT carbenoxolone_NN has_VBZ
        anticonvulsant_NN activities_NNS in_IN PTZ_NNP and_CC MES_NNP models_NNS ._.
        Agents_NNS affecting_VBG the_DT PTZ_NNP model_NN can_MD inhibit_VB petit_NN mal_NN
        seizure_NN [_NN 9_CD ]_NN ._. Thus_RB ,_, carbenoxolone_NN may_MD have_VB activity_NN on_IN
        this_DT kind_NN of_IN seizure_NN ._. Carbenoxolone_NNP also_RB showed_VBD activity_NN
        against_IN MES_NNP ._. This_DT implies_VBZ that_DT carbenoxolone_NN may_MD have_VB
        efficacy_NN in_IN grand_JJ mal_NN seizure_NN [_NN 9_CD ]_NN ._.
        Less_RBR is_VBZ known_VBN about_IN the_DT effects_NNS of_IN carbenoxolone_NN on_IN GJs_NNP ,_,
        although_IN it_PRP has_VBZ been_VBN proposed_VBN that_IN glycyrrhetinic_JJ acid_NN ,_, to_TO
        which_WDT carbenoxolone_NN is_VBZ related_VBN ,_, binds_NNS directly_RB to_TO connexin_NN
        molecules_NNS causing_VBG a_DT conformational_NN change_NN leading_VBG to_TO a_DT
        closure_NN of_IN the_DT junction_NN [_NN 7_CD ]_NN ._. Modeling_NNP studies_NNS indicate_VBP
        that_DT neuronal_NN synchronization_NN can_MD be_VB mediated_JJ by_IN low_JJ
        densities_NNS of_IN GJs_NNP either_DT between_IN dendrites_NNS ,_, as_RB long_RB as_IN these_DT
        dendrites_NNS are_VBP excitable_JJ [_NN 10_CD ]_NN ,_, or_CC between_IN the_DT axons_NNS of_IN
        pyramidal_NN cells_NNS [_NN 11_CD ]_NN ._. Furthermore_RB ,_, the_DT electrotonic_JJ
        coupling_NN could_MD be_VB promoted_VBN during_IN epileptogenesis_NNS [_NN 12_CD 13_CD ]_NN
        ._.
        Optical_NNP imaging_NN of_IN neural_NN activity_NN evoked_JJ by_IN electrical_JJ
        stimulation_NN in_IN the_DT cultured_JJ rat_NN suprachiasmatic_JJ nucleus_NN
        (_( SCN_NNP )_) revealed_VBD that_IN the_DT spread_NN of_IN depolarization_NN was_VBD
        inhibited_VBD by_IN gap_NN junction_NN blockers_NNS (_( halothane_NN ,_, octanol_NN )_) but_CC
        not_RB by_IN a_DT blocker_NN of_IN voltage-depended_JJ Na_NNP +_NN channels_NNS ._.
        Depolarization_NNP propagation_NN was_VBD also_RB inhibited_VBD by_IN muscimol_NN ,_,
        a_DT GABA_NNP 
        A_DT receptor_NN agonist_NN ,_, in_IN a_DT dose_NN dependent_JJ
        manner_NN ,_, and_CC inhibition_NN was_VBD reversed_VBN by_IN bicuculline_NN ,_, a_DT GABA_NNP 
        A_DT receptor_NN antagonist_NN ._. This_DT indicated_VBD
        that_IN the_DT propagation_NN of_IN depolarization_NN between_IN SCN_NNP cells_NNS
        was_VBD inhibited_VBD by_IN GABA_NNP 
        A_DT receptor_NN activation_NN ._. There_EX were_VBD two_CD
        possible_JJ explanations_NNS for_IN this_DT result_NN ._. First_LS ,_, GABA_NNP might_MD
        affect_VB the_DT permeability_NN of_IN gap_NN junction_NN channels_NNS ._. Secondly_RB ,_,
        muscimol_NN might_MD increase_VB the_DT chloride_NN conductance_NN
        independent_JJ of_IN gap_NN junctions_NNS ,_, and_CC might_MD cause_VB a_DT decrease_NN in_IN
        the_DT spread_NN of_IN depolarization_NN ._. Furthermore_RB ,_, muscimol_NN
        inhibited_VBD dye-transfer_JJ between_IN neurons_NNS in_IN the_DT SCN_NNP culture_NN
        in_IN a_DT dose-dependent_JJ fashion_NN ,_, so_IN that_IN GABA_NNP might_MD have_VB
        reduced_VBN gap_NN junction_NN communication_NN between_IN SCN_NNP neurons_NNS via_IN
        the_DT GABAA_NNP receptor_NN [_NN 14_CD ]_NN ._. In_IN that_DT study_NN they_PRP could_MD not_RB
        clarify_VB how_WRB the_DT activation_NN of_IN a_DT GABAA_NNP receptor_NN and_CC
        subsequent_JJ increase_NN in_IN chloride_NN conductance_NN impact_NN gap_NN
        junctions_NNS ._. In_IN studies_NNS ,_, it_PRP has_VBZ been_VBN reported_VBN that_IN increases_NNS
        in_IN intracellular_NN Ca_MD +_NN 2_CD or_CC decreases_NNS in_IN intracellular_NN pH_NN can_MD
        uncouple_NN cells_NNS [_NN 15_CD ]_NN ._. So_IN they_PRP suggest_VBP that_IN a_DT
        participation_NN of_IN the_DT GABA_NNP receptors_NNS in_IN the_DT regulation_NN of_IN Ca_MD
        +_NN 2_CD concentration_NN or_CC intracellular_NN pH_NN could_MD explain_VB the_DT
        uncoupling_VBG effect_NN of_IN muscimol_NN ._. As_IN a_DT matter_NN of_IN fact_NN it_PRP was_VBD
        suggested_VBN that_IN the_DT gap_NN junction_NN coupling_NN state_NN between_IN
        neurons_NNS in_IN SCN_NNP is_VBZ not_RB static_JJ but_CC dynamically_RB regulated_VBN by_IN
        the_DT GABA_NNP 
        A_DT receptor_NN system_NN [_NN 14_CD ]_NN ._. Also_RB in_IN vitro_NN
        guinea-pig_JJ brain_NN preparation_NN prolonged_JJ seizure-like_JJ
        activity_NN elicited_JJ using_VBG a_DT brief_JJ application_NN of_IN bicuculline_NN
        was_VBD abolished_VBN by_IN the_DT GJ_NNP channel_NN blockers_NNS octanol_NN and_CC
        glycyrrhetinic_JJ acid_NN as_RB well_RB as_IN by_IN intracellular_NN
        acidification_NN [_NN 16_CD ]_NN ._.
        It_PRP is_VBZ suggested_VBN that_DT carbenoxolone_NN ,_, by_IN blocking_VBG GJ_NNP
        channels_NNS inhibits_NNS both_DT the_DT induction_NN and_CC duration_NN of_IN
        epilepsy_NN in_IN the_DT in_IN vivo_NN models_NNS of_IN seizures_NNS ._. From_IN previous_JJ
        evidences_NNS we_PRP speculate_VBP that_DT carbenoxolone_NN ,_, by_IN closing_VBG GJ_NNP
        channels_NNS ,_, possibly_RB directly_RB or_CC via_IN the_DT GABAergic_NNP system_NN ,_,
        inhibits_NNS the_DT spread_NN of_IN depolarization_NN waves_NNS in_IN the_DT CNS_NNP and_CC
        peripheral_JJ organs_NNS ._. These_DT could_MD explain_VB the_DT anticonvulsant_NN ,_,
        muscle_NN relaxant_NN and_CC hypnotic_JJ effects_NNS of_IN carbenoxolone_NN ._. But_CC
        further_JJ experiments_NNS need_VBP to_TO establish_VB this_DT hypothesis_NNS ._.
        At_IN anticonvulsant_NN doses_NNS ,_, carbenoxolone_NN produced_VBD a_DT
        hypnotic_JJ effect_NN in_IN the_DT pentobarbitone_NN sleep_NN test_NN and_CC motor_NN
        impairment_NN in_IN the_DT rotarod_NN test_NN ,_, but_CC only_RB at_IN a_DT dose_NN of_IN (_( 400_CD
        mg_NN /_NN kg_NN )_) ,_, which_WDT had_VBD anticonvulsant_NN effect_NN ,_, did_VBD carbenoxolone_NN
        show_NN muscle_NN relaxant_NN activity_NN in_IN the_DT traction_NN test_NN ._.
        In_IN the_DT potentiation_NN of_IN pentobarbitone_NN sleep_NN test_NN ,_,
        carbenoxolone_NN significantly_RB showed_VBD sedative_NN effect_NN ._.
        Glycyrrhetinic_NNP acid_NN is_VBZ an_DT aglycone_NN saponin_NN extracted_VBN from_IN
        licorice_NN root_NN [_NN 7_CD ]_NN and_CC saponines_NNS have_VBP hypnotic_JJ effects_NNS [_NN
        17_CD ]_NN ._. Carbenoxolone_NNP is_VBZ also_RB the_DT succinyl_NN ester_NN of_IN
        glycyrrhetinic_JJ acid_NN ._. Thus_RB ,_, this_DT can_MD explain_VB the_DT sedative_NN
        effect_NN of_IN carbenoxolone_NN ._.
        In_IN the_DT muscle_NN coordination_NN test_NN ,_, carbenoxolone_NN showed_VBD a_DT
        muscle_NN relaxant_NN effect_NN ._. Synchronized_VBN firing_NN is_VBZ a_DT widespread_JJ
        phenomenon_NN in_IN the_DT mammalian_JJ brain_NN [_NN 18_CD 19_CD ]_NN including_VBG the_DT
        motor_NN cortex_NN [_NN 20_CD ]_NN ,_, respiratory_JJ motor_NN neurons_NNS [_NN 21_CD 22_CD ]_NN
        and_CC limb_NN motor_NN neurons_NNS [_NN 23_CD 24_CD ]_NN ._. These_DT studies_NNS have_VBP
        demonstrated_VBN the_DT presence_NN of_IN gap_NN junctions_NNS in_IN many_JJ levels_NNS
        of_IN the_DT motor_NN system_NN ,_, in_IN both_DT motor_NN neurons_NNS and_CC in_IN premotor_NN
        pattern_NN generating_NN circuits_NNS ._. Further_RB gap_NN junction_NN coupling_NN
        (_( GJC_NNP )_) has_VBZ brought_VBN about_IN robust_JJ coordination_NN patterns_NNS ,_, even_RB
        in_IN the_DT absence_NN of_IN chemical_NN synapses_NNS ,_, and_CC has_VBZ been_VBN shown_VBN to_TO
        mediate_VB synchronization_NN of_IN neurons_NNS during_IN motor_NN behaviors_NNS [_NN
        25_CD ]_NN ._.
        On_IN the_DT other_JJ hand_NN ,_, as_RB yet_RB there_EX is_VBZ no_DT information_NN about_IN
        the_DT effects_NNS of_IN carbenoxolone_NN in_IN the_DT muscle_NN tissues_NNS ;_:
        therefore_RB ,_, the_DT possibility_NN exists_VBZ that_IN these_DT channels_NNS may_MD
        be_VB in_IN muscles_NNS and_CC synchronize_VBP the_DT firing_NN between_IN muscle_NN
        cells_NNS ._. Carbenoxolone_NNP by_IN blocking_VBG these_DT channels_NNS causes_NNS
        motor_NN impairment_NN ._. However_RB ,_, a_DT demonstration_NN of_IN whether_IN these_DT
        channels_NNS are_VBP ,_, in_IN fact_NN ,_, capable_JJ of_IN mediating_VBG electrical_JJ
        transmission_NN requires_VBZ physiological_JJ experiments_NNS ._.
        Thus_RB ,_, we_PRP conclude_VBP that_DT carbenoxolone_NN has_VBZ anticonvulsant_NN ,_,
        muscle_NN relaxant_NN and_CC hypnotic_JJ effects_NNS in_IN the_DT in_IN vivo_NN models_NNS ,_,
        possibly_RB via_IN blocking_VBG GJ_NNP channels_NNS ._. The_DT exact_JJ mechanism_NN of_IN
        these_DT effects_NNS needs_VBZ further_JJ investigation_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Chemicals_NNS
          Carbenoxolone_NNP ,_, pentylenetetrazole_NN and_CC pentobarbitone_NN
          were_VBD obtained_VBN from_IN Sigma_NNP ._. Diazepam_NNP was_VBD from_IN Daru_NNP Pakhsh_NNP
          Pharmaceutical_NNP Co_NNP ._. ,_, Iran_NNP in_IN the_DT form_NN of_IN ampoule_NN (_( 2_CD mg_NN /_NN 10_CD
          ml_NN )_) ._.
          All_DT drugs_NNS were_VBD dissolved_VBN in_IN a_DT physiological_JJ saline_NN
          solution_NN ._.
        
        
          Animals_NNS
          Male_NNP BALB_NNP /_NN c_SYM mice_NNS ,_, 25_CD -_: 30_CD g_SYM were_VBD obtained_VBN from_IN the_DT
          animal_NN house_NN of_IN Pharmaceutical_NNP Research_NNP Center_NNP ,_, Bu-_NNP Ali_NNP
          Research_NNP Institute_NNP of_IN Mashhad_NNP University_NNP of_IN Medical_NNP
          Sciences_NNPS ._. The_DT animals_NNS were_VBD housed_VBN in_IN colony_NN rooms_NNS with_IN
          12_CD /_NN 12_CD h_NN light_JJ /_NN dark_JJ cycle_NN at_IN 21_CD ±_NN 2_CD °_NN C_NNP and_CC had_VBD free_JJ access_NN
          to_TO food_NN and_CC water_NN ._.
          All_DT animal_NN experiments_NNS were_VBD carried_VBN out_IN in_IN accordance_NN
          with_IN Mashhad_NNP University_NNP of_IN Medical_NNP Sciences_NNPS ,_, Ethical_NNP
          Committee_NNP Acts_NNP ._.
        
        
          Anticonvulsant_NNP activity_NN
          
            Pentylenetetrazole_NNP (_( PTZ_NNP )_) Seizure_NNP model_NN
            Mice_NNS were_VBD divided_VBN into_IN groups_NNS of_IN seven_CD ._. Diazepam_NNP ,_,
            carbenoxolone_NN and_CC normal_JJ saline_NN were_VBD injected_VBN
            intraperitoneally_RB (_( i_NNP ._. p_NN )_) 30_CD ,_, 60_CD and_CC 60_CD min_NN respectively_RB ,_,
            before_IN the_DT administration_NN of_IN pentylenetetrazole_NN (_( i_NNP ._. p_NN ,_,
            90_CD mg_NN /_NN kg_NN )_) ._. The_DT onset_NN of_IN a_DT general_JJ clonus_JJ was_VBD used_VBN as_IN
            the_DT endpoint_NN ._. The_DT general_JJ clonus_JJ was_VBD characterized_VBN by_IN
            forelimb_NN clonus_JJ followed_VBN by_IN full_JJ clonus_JJ of_IN the_DT body_NN ._.
            The_DT time_NN taken_VBN before_IN the_DT onset_NN of_IN clonic_JJ convulsions_NNS ,_,
            the_DT duration_NN of_IN clonic_JJ convulsions_NNS ,_, and_CC the_DT percentage_NN
            of_IN seizure_NN and_CC mortality_NN protection_NN were_VBD recorded_VBN [_NN 26_CD
            ]_NN ._.
          
          
            Maximal_NNP electroshock_NN seizure_NN (_( MES_NNP )_) model_NN
            Mice_NNS were_VBD divided_VBN into_IN groups_NNS of_IN seven_CD ._. An_DT
            alternating_VBG current_JJ stimulus_NN of_IN 50_CD Hz_NNP and_CC 150_CD mA_NN
            through_IN ear-clip_JJ electrodes_NNS was_VBD delivered_VBN for_IN 0_CD ._. 2_CD sec_NN
            to_TO the_DT experimental_JJ animals_NNS ._. A_DT drop_NN of_IN 0_CD ._. 9_CD %_NN saline_NN
            solution_NN was_VBD poured_VBN into_IN each_DT ear_NN prior_RB to_TO placing_VBG the_DT
            electrodes_NNS ._. Diazepam_NNP ,_, carbenoxolone_NN and_CC normal_JJ saline_NN
            are_VBP injected_VBN intraperitoneally_RB (_( i_NNP ._. p_NN )_) 30_CD ,_, 60_CD and_CC 60_CD min_NN ,_,
            respectively_RB before_IN the_DT test_NN ._. The_DT duration_NN of_IN tonic_NN
            convulsion_NN (_( a_DT tonic_NN extension_NN of_IN the_DT hindlimb_NN )_) ,_, the_DT
            percentage_NN of_IN seizure_NN and_CC the_DT mortality_NN protection_NN were_VBD
            recorded_VBN [_NN 26_CD ]_NN ._.
          
          
            Potentiation_NNP of_IN sodium_NN pentobarbitone_NN
            sleep_NN
            Mice_NNS were_VBD divided_VBN into_IN groups_NNS of_IN ten_CD ._. Carbenoxolone_NNP
            at_IN doses_NNS 100_CD ,_, 200_CD and_CC 300_CD mg_NN /_NN kg_NN and_CC diazepam_NN at_IN the_DT
            dose_NN of_IN 1_CD mg_NN /_NN kg_NN and_CC normal_JJ saline_NN (_( 10_CD ml_NN /_NN kg_NN )_) were_VBD
            injected_VBN interaperitonially_RB to_TO separate_JJ groups_NNS ._. 1_LS h_NN
            after_IN receiving_VBG carbenoxolone_NN and_CC normal_JJ saline_NN and_CC 30_CD
            min_NN after_IN receiving_VBG diazepam_NN ,_, each_DT animal_NN was_VBD injected_VBN
            sodium_NN pentobarbitone_NN (_( 30_CD mg_NN /_NN kg_NN ,_, i_NNP ._. p_NN )_) ._. The_DT sleeping_VBG
            time_NN was_VBD noted_VBN by_IN recording_VBG the_DT interval_NN between_IN the_DT
            loss_NN and_CC regaining_VBG of_IN righting_VBG reflex_JJ [_NN 27_CD ]_NN ._.
          
          
            Muscle_NNP relaxant_NN activity_NN
            This_DT was_VBD examined_VBN by_IN :_: (_( a_DT )_) Traction_NNP test_NN and_CC (_( b_SYM )_)
            Rotarod_NNP test_NN
          
          
            Traction_NNP test_NN
            Forepaws_NNP of_IN a_DT mouse_NN were_VBD placed_VBN on_IN a_DT small_JJ twisted_JJ
            wire_NN rigidly_RB supported_VBD above_IN a_DT bench_NN top_JJ ._. Normal_NNP mice_NNS
            grasped_JJ the_DT wire_NN with_IN forepaws_NNS and_CC when_WRB allowed_VBN to_TO hang_VB
            free_JJ ,_, placed_VBN at_IN least_JJS one_CD hind_NN foot_NN on_IN the_DT wire_NN within_IN
            5_CD seconds_NNS ._. Inability_NNP to_TO put_VB up_RP at_IN least_JJS one_CD hind_NN foot_NN
            constituted_VBD failure_NN to_TO the_DT traction_NN [_NN 28_CD ]_NN ._.
            The_DT test_NN was_VBD conducted_VBN in_IN groups_NNS of_IN ten_CD previously_RB
            screened_VBD animals_NNS ,_, 1_CD h_NN after_IN the_DT injection_NN of_IN either_DT
            saline_NN (_( 10_CD ml_NN /_NN kg_NN )_) or_CC carbenoxolone_NN (_( 200_CD ,_, 300_CD and_CC 400_CD
            mg_NN /_NN kg_NN )_) and_CC 30_CD min_NN after_IN diazepam_NN (_( 0_CD ._. 125_CD ,_, 0_CD ._. 25_CD ,_, 0_CD ._. 5_CD
            mg_NN /_NN kg_NN )_) ._.
          
          
            Rotarod_NNP test_NN
            Motor_NNP coordination_NN and_CC balance_NN were_VBD tested_VBN using_VBG
            accelerating_VBG rotarod_NN (_( TSE_NNP RotaRod_NNP System_NNP )_) ._. Mice_NNS were_VBD
            placed_VBN on_IN a_DT horizontal_NN metal_NN coated_VBN rod_NN with_IN rubber_NN (_( 3_CD
            cm_NN diameter_NN )_) rotating_VBG at_IN an_DT initial_JJ speed_NN of_IN 10_CD
            rpm_NN /_NN min_NN ._. Terminal_NNP speed_NN of_IN the_DT rod_NN was_VBD 20_CD rpm_NN in_IN
            accelerated_VBD studies_NNS and_CC rotational_NN velocity_NN of_IN the_DT rod_NN
            was_VBD linearly_RB increased_VBN from_IN 10_CD to_TO 20_CD rpm_NN within_IN 20_CD s_VBZ ._.
            The_DT time_NN each_DT animal_NN was_VBD able_JJ to_TO maintain_VB its_PRP$ balance_NN
            walking_VBG on_IN top_NN of_IN the_DT rod_NN was_VBD measured_VBN ._. Mice_NNS were_VBD given_VBN
            two_CD trials_NNS with_IN a_DT maximum_NN time_NN of_IN 300_CD s_VBZ and_CC a_DT 30_CD to_TO 60_CD
            min_NN intertrial_NN rest_NN interval_NN ._. [_NN 29_CD ]_NN ._. Before_IN the_DT
            beginning_NN of_IN all_DT experiments_NNS ,_, the_DT riding_VBG ability_NN of_IN the_DT
            animals_NNS in_IN the_DT rotarod_NN was_VBD checked_VBN ._. Thus_RB ,_, the_DT mice_NNS were_VBD
            initially_RB put_VB on_IN a_DT rotating_VBG rod_NN ,_, and_CC mice_NNS that_WDT
            immediately_RB dropped_VBD off_RP (_( within_IN 30_CD s_VBZ )_) were_VBD removed_VBN from_IN
            the_DT experiment_NN ._.
            Mice_NNS were_VBD divided_VBN into_IN groups_NNS of_IN ten_CD ._. Diazepam_NNP (_( 1_CD
            mg_NN /_NN kg_NN )_) ,_, carbenoxolone_NN (_( 100_CD ,_, 200_CD and_CC 300_CD mg_NN /_NN kg_NN )_) and_CC
            normal_JJ saline_NN (_( 10_CD ml_NN /_NN kg_NN )_) were_VBD injected_VBN 30_CD ,_, 60_CD and_CC 60_CD
            minutes_NNS respectively_RB ,_, before_IN the_DT test_NN ._.
          
        
        
          Statistical_NNP analysis_NN
          The_DT dose_NN of_IN carbenoxolone_NN to_TO produce_VB an_DT anticonvulsant_NN
          (_( ED_NNP 50_CD )_) effect_NN in_IN 50_CD %_NN of_IN animals_NNS and_CC its_PRP$ associated_VBN 95_CD %_NN
          confidence_NN limits_NNS was_VBD calculated_VBN by_IN Litchfield_NNP and_CC
          Wilcoxon_NNP methods_NNS (_( PHARM_NNP /_NN PCS_NNP Version_NNP 4_LS )_) ._. Data_NNP were_VBD
          expressed_VBN as_IN mean_NN values_NNS ±_NN SEM_NNP and_CC tested_VBN with_IN variance_NN
          analysis_NN followed_VBN by_IN the_DT multiple_JJ comparison_NN tests_NNS to_TO
          Tukey-_NNP Kramer_NNP for_IN the_DT anticonvulsant_NN activity_NN and_CC for_IN the_DT
          sleeping_VBG activity_NN ._.
          Fischer_NNP 's_POS exact_JJ test_NN (_( two_CD sided_VBN )_) in_IN traction_NN test_NN and_CC
          one-way_JJ ANOVA_NNP with_IN post_NN hoc_FW comparisons_NNS analyzed_VBN by_IN
          Dunnetts_NNP test_NN were_VBD used_VBN in_IN the_DT accelerod_NN performance_NN ._.
        
      
    
  
